Mobile

A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haem...

Update Il y a 4 ans
Reference: EUCTR2006-004879-35

A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors.Trial phase: 2

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the safety of five escalating doses of NN1731 in haemophilia subjects with inhibitors being treated for acute joint bleeds.

Inclusion criteria

  • Haemophilia A with anti factor VIII and Haemophilia B with anti factor IX

Links